Idorsia

Idorsia's Tryvio crosses FDA finish line, offering new mechanism to treat hypertension
Fierce Pharma
Wed, 03/20/24 - 09:49 pm
JNJ
Idorsia
Tryvio
hypertension
FDA
Viatris splashes out $350m on pair of Idorsia therapies
Pharmaphorum
Wed, 02/28/24 - 10:45 am
Viatris
Idorsia
lupus
myocardial infarction
selatogrel
cenerimod
J&J sends blood pressure drug back to Idorsia
BioPharma Dive
Wed, 09/6/23 - 11:54 am
Idorsia
JNJ
aprocitentan
hypertension
Sleepless nights for 500 Idorsia staff as biotech halves cash burn to outlast weak insomnia drug sales
Fierce Biotech
Fri, 07/21/23 - 10:00 am
Idorsia
layoffs
Quviviq
Idorsia in Exclusive Talks for up to CHF 400 Million Strategic Deal for Asia Pacific (ex-China) Operations
Globe Newswire
Tue, 06/6/23 - 09:58 am
Idorsia
Asia Pacific
Defense Department backs new study of Idorsia's Quviviq as a treatment for PTSD
Fierce Pharma
Wed, 05/10/23 - 09:58 am
Idorsia
PTSD
Department of Defense
Quviviq
Idorsia shares sink on ‘unexpected’ failure of drug study
BioPharma Dive
Mon, 02/6/23 - 06:07 pm
Idorsia
clinical trials
clazosenta
Biotech’s key upcoming clinical results
EP Vantage
Tue, 12/20/22 - 10:27 am
clinical trials
Acadia Pharmaceuticals
Argenx
Arrowhead Pharmaceuticals
Biomarin
BioNTech
Daiichi Sankyo
Day One
EQRx
Fate Therapeutics
FibroGen
Gilead Sciences
Idorsia
Immunogen
Intellia Therapeutics
Karuna Therapeutics
Moderna Therapeutics
Regeneron
Roche
Travere Therapeutics
Vaxcyte
Neurocrine's $50M bet on Idorsia drug flames out in second PhII
Endpoints
Wed, 12/7/22 - 09:58 am
Neurocrine
Idorsia
clinical trials
NBI-827104
epileptic encephalopathy
J&J, Idorsia plan filings for aprocitentan data in resistant hypertension
Pharmaphorum
Tue, 11/8/22 - 10:33 pm
JNJ
Idorsia
aprocitentan
hypertension
resistant hypertension
J&J's $230M blood pressure bet hits phase 3 endpoint, but questions linger about blockbuster potential
Fierce Biotech
Mon, 05/23/22 - 10:19 am
JNJ
hypertension
Idorsia
clinical trials
aprocitentan
Idorsia drug fails to quell binge eating in midphase trial, driving biotech to abandon the indication
Fierce Biotech
Tue, 05/10/22 - 10:39 am
Idorsia
clinical trials
ACT-539313
binge eating disorder
Actelion
Idorsia's recently approved insomnia drug Quviviq hits the shelves
Bizjournals
Wed, 05/4/22 - 05:43 pm
Idorsia
drug launches
insomnia
Quviviq
Idorsia scores FDA go-ahead for insomnia drug Quviviq to rival Merck’s Belsomra, Eisai’s Dayvigo
Fierce Pharma
Mon, 01/10/22 - 11:37 pm
Idorsia
Quviviq
insomnia
FDA
Merck
Belsomra
Idorsia hoping to make its dreams come true with a new insomnia alliance
Fierce Pharma
Tue, 12/14/21 - 11:06 am
Idorsia
insomnia
pharma marketing
daridorexant
Idorsia sets itself up for failure
EP Vantage
Mon, 11/1/21 - 10:57 pm
Idorsia
cenerimod
lupus
clinical trials
Late-stage letdown for lucerastat dents Idorsia stock
Pharma Letter
Mon, 10/11/21 - 10:20 am
Idorsia
clinical trials
lucerastat
Fabry disease
Santhera bags DMD drug in 3-way deal with Idorsia and ReveraGen
Fierce Biotech
Wed, 09/2/20 - 11:04 am
Santhera
vamorolone
Duchenne Muscular Dystrophy
Idorsia
ReveraGen
Second PhIII study for Idorsia's sleep drug returns positive results, but also raises new questions
Endpoints
Tue, 07/7/20 - 10:35 am
Idorsia
daridorexant
insomnia
clinical trials
Idorsia's rival to Merck's insomnia drug clears phase 3 test
Fierce Biotech
Mon, 04/20/20 - 10:47 am
Idorsia
Merck
insomnia
clinical trials
JNJ
daridorexant
Belsorma

Pages